Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062825 | 0.83 | PARP1 (0.65) | PARP1 | |
| SCHEMBL3068159 | 0.81 | PARP1 (0.62) | PARP1 | |
| SCHEMBL3082811 | 0.80 | PARP1 (0.60) | PARP1 | |
| SCHEMBL3062499 | 0.79 | PARP1 (1.00) | PARP1 | |
| SCHEMBL3068011 | 0.78 | PARP1 (0.98) | PARP1 | |
| SCHEMBL3068611 | 0.77 | PARP1 (0.83) | PARP1KDR | |
| SCHEMBL3072839 | 0.72 | PARP1 (0.72) | PARP1PDGFRBKDR | |
| SCHEMBL8072073 | 0.72 | PARP1 (0.58) | PARP1 | |
| SCHEMBL13146581 | 0.65 | PDE2A (0.45) | PARP1SLC2A1 | |
| SCHEMBL13146599 | 0.64 | PDE2A (0.47) | PARP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-7790721-B2 | Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2114948-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008082887-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885PDGFRB 1436/4885KDR 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.